The turbulent times continued for Indian Pharma space in Q2 FY19. The performance in the regulated markets of US and Europe continued to be a drag for majority of players as pricing pressure and lower new product launches continuing to be a headwind. Though the street is well aware about the narrative on margin pressure […]

Read More